Tirzepatide added to insulin pump for type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether adding a weekly injection of tirzepatide (a drug that helps with blood sugar and weight) can improve glucose control in adults with type 1 diabetes who already use an automated insulin pump. It may help you if your blood sugar is not at target despite using a pump.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have had type 1 diabetes for at least 12 months.
- You must be using an automated insulin delivery system (a pump that adjusts insulin) for at least 3 months.
- Your HbA1c (average blood sugar over 3 months) should be between 6.5% and 10%.
- Your BMI (body mass index) must be 23 or higher.
- You must be willing to take a weekly injection of tirzepatide (a GIP/GLP-1 drug) for 16 weeks and use a Dexcom G7 continuous glucose monitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication that may help your body respond better to insulin. It's for people with type 1 diabetes who use an automated insulin pump and are willing to take a daily pill for 12 weeks.
This trial tests if adding tirzepatide (a once-weekly injection) to an automated insulin pump system (Control-IQ) helps adults with type 1 diabetes better manage their blood sugar. It requires using the Tandem Control-IQ pump and counting carbohydrates.
This trial tests whether tirzepatide, a medication that helps control blood sugar and weight, can safely improve how your body handles sugar when you have type 1 diabetes. The study looks at short-term effects and may help people who are overweight and use an insulin pump or automated system.
This study tests a weekly injection called tirzepatide to see if it helps people with type 1 diabetes who are overweight or obese. The goal is to improve blood sugar control and help with weight loss.
This study tests a weekly injection called tirzepatide in people with type 1 diabetes who are overweight or have obesity. The goal is to see if it helps with blood sugar control and weight loss when added to insulin therapy.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
Hear when a new Type 1 Diabetes (T1D) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.